Open Access iconOpen Access

ARTICLE

crossmark

Metochalcone induces senescence-associated secretory phenotype via JAK2/STAT3 pathway in breast cancer

JIANBO ZHOU1,2,3, FENG WAN2,4, BIN XIAO5, XIN LI1, CHENG PENG2,*, FU PENG1,3,*

1 Department of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu, China
2 State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China
3 Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, Sichuan University, Chengdu, China
4 Chengdu No. 1 Pharmaceutical Co., Ltd., Pengzhou, China
5 Chengdu Push Bio-Technology Co., Ltd., Chengdu, China

* Corresponding Authors: CHENG PENG. Email: email; FU PENG. Email: email

(This article belongs to the Special Issue: Application of Multi-omics Analysis in Cancer Immunotherapy)

Oncology Research 2024, 32(5), 943-953. https://doi.org/10.32604/or.2023.044775

Abstract

Breast and lung cancers are the leading causes of mortality and most frequently diagnosed cancers in women and men, respectively, worldwide. Although the antitumor activity of chalcones has been extensively studied, the molecular mechanisms of isoliquiritigenin analog 2', 4', 4-trihydroxychalcone (metochalcone; TEC) against carcinomas remain less well understood. In this study, we found that TEC inhibited cell proliferation of breast cancer BT549 cells and lung cancer A549 cells in a concentration-dependent manner. TEC induced cell cycle arrest in the S-phase, cell migration inhibition in vitro, and reduced tumor growth in vivo. Moreover, transcriptomic analysis revealed that TEC modulated the activity of the JAK2/STAT3 and P53 pathways. TEC triggered the senescence-associated secretory phenotype (SASP) by repressing the JAK2/STAT3 axis. The mechanism of metochalcone against breast cancer depended on the induction of SASP via deactivation of the JAK2/STAT3 pathway, highlighting the potential of chalcone in senescence-inducing therapy against carcinomas.

Graphical Abstract

Metochalcone induces senescence-associated secretory phenotype via JAK2/STAT3 pathway in breast cancer

Keywords


Cite This Article

APA Style
ZHOU, J., WAN, F., XIAO, B., LI, X., PENG, C. et al. (2024). Metochalcone induces senescence-associated secretory phenotype via JAK2/STAT3 pathway in breast cancer. Oncology Research, 32(5), 943-953. https://doi.org/10.32604/or.2023.044775
Vancouver Style
ZHOU J, WAN F, XIAO B, LI X, PENG C, PENG F. Metochalcone induces senescence-associated secretory phenotype via JAK2/STAT3 pathway in breast cancer. Oncol Res. 2024;32(5):943-953 https://doi.org/10.32604/or.2023.044775
IEEE Style
J. ZHOU, F. WAN, B. XIAO, X. LI, C. PENG, and F. PENG "Metochalcone induces senescence-associated secretory phenotype via JAK2/STAT3 pathway in breast cancer," Oncol. Res., vol. 32, no. 5, pp. 943-953. 2024. https://doi.org/10.32604/or.2023.044775



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 672

    View

  • 162

    Download

  • 0

    Like

Share Link